A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon®) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP®) in a fixed-dose regimen in women undergoing ovarian stimulation

Human Reproduction

Volumn 14, Issue 10, 1999, Pages 2442-2447

  Hoomans, Eric H M ^a   Andersen, Anders Nyboe ^b   Loft, Anne ^b   Leerentveld, Robert A ^c   Van Kamp, Anton A ^c   Zech, Herbert ^d  

^a NV ORGANON   (Netherlands)

^b Mental Health Services CPH   (Denmark)

^c ISALA HOSPITAL   (Netherlands)

^d Inst Vitro Fertilisierung Embryo T   (Austria)

Author keywords

IVF; Metrodin hHP ; Puregon ; Recombinant FSH; Urinary FSH

Indexed keywords

RECOMBINANT FOLLITROPIN; UROFOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO DEVELOPMENT; FEMALE; FERTILIZATION IN VITRO; FREEZING; HUMAN; HUMAN CELL; INFERTILITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OOCYTE; OVARY FUNCTION; PREGNANCY RATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032824742     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/14.10.2442     Document Type: Article

References (19)

1. Anobile, C.J., Talbot, J.A., McCann, S.J. et al. (1998) Glycoform composition of serum gonadotrophins through the normal menstrual cycle and in the post-menopausal state. Mol. Hum. Reprod., 4, 631-639.
2. Bergh, C., Howles, C.M., Borg, K. et al. (1997) Recombinant human follicle stimulating hormone (r-hFSH, Gonal-F) versus highly purified urinary FSH (Metrodin HP) - Results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum. Reprod., 12, 2133-2139.
3. Camier, B., the French multicentre trialists, Howles, C.M. and Truong, F. (1998) A multicentre, prospective, randomized study to compare a low-dose protocol versus conventional administration of recombinant human follicle stimulating hormone (Gonal-F®) in normo-responder women undergoing IVF/ICSI. Hum Reprod., 13 (Suppl.), Abstract P-058, 159.
4. De Leeuw, R., Mulders, J., Voortman, G. et al. (1996) Structure-function relationship of recombinant follicle stimulating hormone (Puregon®). Mol. Hum. Reprod., 2, 361-369.
5. Devroey, P., Tournaye, H., Van Steirteghem, A. et al. (1998) The use of a 100 IU starting dose of recombinant FSH (Puregon®) in in-vitro fertilization. Hum. Reprod., 13, 565-566.
6. Flamigni, C., Venturoli, S., Dal Prato, L. and Porcu, E. (1994) Purified FSH: characteristics and applications. In Filicori, M. and Flamigni, C. (eds), Ovulation Induction: Basic Science and Clinical Advances. Elsevier Science bv, Amsterdam, pp. 125-134.
7. Lambert, A., Rodgers, M., Mitchell, R. et al. (1995) In-vitro biopotency of glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP. Mol. Hum. Reprod., 10, 1928-1935.
8. Lambert, A., Talbot, J.A., Anobile, C.J. and Robertson, W.R. (1998) Gonadotrophin heterogeneity and biopotency: implications for assisted reproduction. Mol. Hum. Reprod., 4, 619-629.
9. Matikainen, T., Leeuw de, R., Mannaerts, B. and Huthaniemi, I. (1994) Circulating bioactive and immunoreactive recombinant follicle stimulating hormone (Org 32489) after administration to gonadotropin-deficient volunteers. Fertil. Steril., 61, 62-69.
10. Olijve, W., Boer de, W., Mulders, J.W.M. and Van Weezenbeek, P.M.G.F. (1996) Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon). Mol. Hum. Reprod., 2, 371-382.
11. Olivennes, F. and Frydman, R. (1998) Friendly IVF: the way of the future? Hum. Reprod., 13, 1121-1124.
12. Out, H.J., Mannaerts, B.M.J.L., Driessen, S.G.A.J. and Coelingh Bennink, H.J.T. (1995) A prospective, randomised, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum. Reprod., 10, 2534-2540.
13. Out, H.J., Driessen, S.G.A.J., Mannaerts, B.M.J.L. and Coelingh Bennink, H.J.T. (1997) Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertil. Steril., 68, 138-142.
14. Out, H.J., Lindenberg, S., Eldar-Geva, T. et al. (1999) A prospective, randomized, double-blind clinical trail to study the efficacy and efficiency of a fixed daily dose of recombinant follicle stimulating hormone (Puregon®) in women undergoing controlled ovarian hyperstimulation. Hum. Reprod., 14, 662-627.
15. Porter, R.N., Smith, W. and Craft, I.L. (1984) Induction of ovulation for in vitro fertilization using buserelin and gonadotrophins. Lancet, 2, 1284-1285.
16. Staessen, C., Camus, M., Khan, I., Smitz, J. et al. (1989) An 18-month survey of infertility treatment by in vitro fertilization, gamete and zygote intrafallopian transfer, and replacement of frozen-thawed embryos. J. In Vitro Fertil. Embryo Transfer, 6, 22-29.
17. Ulloa-Aguirre, A., Midgley, A.R. Jr, Beitins, I.Z. and Padmanabhan, V. (1995) Follicle-stimulating isonormones: characterization and physiological relevance. Endocr. Rev., 16, 765-787.
18. Vandervorst, M. and Devroey, P. (1997) Recombinant FSH: results in assisted reproduction. In Filicori, M. and Flamigni, C. (eds), Ovulation Induction: Update '98: the Proceedings of the 2nd World Conference on Ovulation Induction. Parthenon Publishing Group, Camforth, UK. pp. 137-146.
19. World Health Organization (1992) Normal values of semen variables (Appendix IA). In WHO Laboratory Manual for the Examination of Human Semen and Sperm-cervical Mucus Interaction. Cambridge University Press, Cambridge, UK, pp. 43-44.